Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Li Kang has a total of 204 co-authors. Here are the top co-authors by number of shared publications:

  • David H. Wasserman

    Department of Molecular Physiology and Biophysics, Mouse Metabolic Phenotyping Center, Vanderbilt University, Nashville, TN, USA

    16 shared publications
  • Freyja D. James

    Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN

    9 shared publications
  • Deanna P. Bracy

    Department of Molecular Physiology and Biophysics and Mouse Metabolic Phenotyping Centre, Vanderbilt University, Nashville, Tennessee

    7 shared publications
  • David H. Wasserman

    Vanderbilt University

    6 shared publications
  • Robert S. Lee-Young

    Cellular and Molecular Metabolism Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia

    6 shared publications
  • Mary E. Lustig

    Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, United States of America

    5 shared publications

Latest Publications

  • Open Access

    A Novel Role of Hyaluronan and Its Membrane Receptors, CD44 and RHAMM, in Obesity-Related Kidney Pathology

    by Bingxue Qi, Vishal Musale, Xiong Weng, Ayman K. Banah, Alexander Lawlor, Colin E. Murdoch, Abigail C. Lay, Kate J. Heesom, Richard J. M. Coward, Christopher L. O’connor, et al.

    Obesity-related kidney pathology (ORKP) is a major global issue that contributes to diabetic nephropathy and kidney cancer and leads to chronic/end-stage kidney disease. Current treatments for ORKP are limited because of the incomplete understanding of the disease pathogenesis. Here, we identified a novel role for hyaluronan (HA) and its membrane receptors, CD44 and RHAMM, in this condition. Obesity-induced increases in HA deposition and CD44 and RHAMM expression are detrimental to the kidney via activation of the TGF-β1/Smad2/3, P38/JNK MAPK, and ROCK/ERK pathways, leading to glomerulopathy, tubular injury, inflammation, albuminuria, and elevated serum creatinine concentrations. Either pharmacological or genetic ablation of HA, CD44, or RHAMM reverses these obesity-driven pathologies in vivo. We further established a mechanistic link between renal insulin resistance and ECM remodelling using human kidney cells in vitro, providing insight into the cell type-specific role of HA, CD44, and RHAMM in the pathogenesis of ORKP. Finally, analysis of glomerular and tubular fractions of human kidney biopsy samples revealed increased expression of CD44 and RHAMM in chronic kidney disease and diabetic nephropathy, and their expression correlated with markers of kidney dysfunction. Our findings provide evidence for HA-CD44/RHAMM as a potential therapeutic target in ORKP and subsequent prevention of chronic kidney disease. While previous studies have implicated CD44 and RHAMM in renal disease and fibrosis, our work for the first time provides an integrated analysis of both receptors in the context of ORKP.


  • Open Access

    Eplerenone improves kidney function and cardiac performance in obese male mice

    by Ayman K. Banah, Bingxue Qi, Ryan Koh, Alexander Lawlor, Tianzhen Wang, Vishal Musale, Joanne Mains, Colin E. Murdoch, Li Kang

    Aims: Renin‐angiotensin‐aldosterone system (RAAS) activation mediates obesity‐associated cardiorenal dysfunction. Due to an incomplete understanding of the molecular mechanisms, the clinical use of RAAS antagonism in obesity‐associated cardiometabolic complications remains uncertain. The present study investigated the effects and associated molecular mechanisms of eplerenone, a selective mineralocorticoid receptor antagonist, in the heart and kidney of obesity. Methods: Male C57BL/6 mice were fed a high‐fat diet (HFD) for 12 weeks before receiving either vehicle or eplerenone treatments for 30 days while maintained on HFD. Cardiac function was measured by pressure–volume (PV) loop analyses. Renal function was assessed by renal morphology and serum creatinine concentrations. Chow‐fed mice were used as lean controls. Results: HFD feeding impaired cardiac and renal function in mice, evidenced by elevated blood pressures, stroke work, Tau, glomerular hypertrophy and tubular injury. Eplerenone treatment caused weight loss, which was attributed to a loss in fat mass. Moreover, eplerenone treatment ameliorated both HFD‐induced cardiac and renal dysfunction, including a decrease in stroke volume, cardiac output and stroke work; an increase in ejection fraction; and a decrease in glomerular hypertrophy, tubular injury, renal fibrosis and serum creatinine concentrations. Mechanistically, eplerenone decreased CD44 but increased RHAMM and TGF‐β expression in the heart. In contrast, eplerenone caused a decrease in the hyaluronan‐CD44/RHAMM pathway, TGF‐β, IL‐6 and phosphorylation of Akt and JNK in the kidney. Conclusion: Eplerenone treatment improved kidney function and cardiac performance in obese male mice. The potential link between the mineralocorticoid receptor and the hyaluronan‐CD44/RHAMM pathway is novel and has not been previously reported.


  • Open Access

    Genetic Deletion of RHAMM Alleviates Hepatic Oxidative Stress, Reversing Thyroid Stimulating Hormone Elevation in Male Obese Mice

    by Tianzhen Wang, Helin Sun, Ayman K. Banah, Xiong Weng, Sharadha Dayalan Naidu, Dot Kisielewski, Abel Ang, John D. Hayes, Albena T. Dinkova-Kostova, Li Kang

    Objective: Obesity induces hypothyroidism with unknown mechanisms. This study investigates the role of (Receptor for Hyaluronan-Mediated Motility (RHAMM) in obesity-associated thyroid dysfunction, focusing on hepatic oxidative stress. Methods: Global RHAMM-deficient mice and their wildtype littermate controls were fed a normal chow diet or high-fat diet (HFD) for 16 weeks. Thyroid function was evaluated by measuring plasma thyroid-stimulating hormone (TSH) levels. The hepatic oxidative response was assessed by measuring signaling pathways associated with nuclear factor erythroid 2-related factor 2 (Nrf2) activity. Results: HFD feeding increased plasma TSH levels in male mice but not in female mice. RHAMM deletion in male mice mitigated HFD-induced TSH elevation, which was associated with enhanced hepatic antioxidant defenses and reduced inflammation. This was evidenced by elevated expression of the Nrf2 target gene NAD(P)H: quinone oxidoreductase 1 (Nqo1), reduced protein carbonylation and nitration levels, and reduced expression of the pro-inflammatory cytokines IL-1β and TNF-α in livers of male RHAMM-deficient mice. Mechanistically, RHAMM deletion decreased AKT/ERK signaling, increased GSK3 signaling, increased CD44 protein expression, and increased Nqo1 levels in the liver. Conclusions: RHAMM promotes obesity-induced thyroid dysfunction by regulating oxidative stress and inflammation in male mice. Targeting RHAMM may provide a novel therapeutic strategy for mitigating obesity-related endocrine and metabolic disorders.


  • Open Access

    O‐linked β‐N‐acetylglucosamine (O‐GlcNAc) modification: Emerging pathogenesis and a therapeutic target of diabetic nephropathy

    by Bingxue Qi, Yang Chen, Siyang Chai, Xiaodan Lu, Li Kang

    Aims: O‐Linked β‐N‐acetylglucosamine (O‐GlcNAc) modification, a unique post‐translational modification of proteins, is elevated in diabetic nephropathy. This review aims to summarize the current knowledge on the mechanisms by which O‐GlcNAcylation of proteins contributes to the pathogenesis and progression of diabetic nephropathy, as well as the therapeutic potential of targeting O‐GlcNAc modification for its treatment.Methods: Current evidence in the literature was reviewed and synthesized in a narrative review.Results: Hyperglycemia increases glucose flux into the hexosamine biosynthesis pathway, which activates glucosamino‐fructose aminotransferase expression and activity, leading to the production of O‐GlcNAcylation substrate UDP‐GlcNAc and an increase in protein O‐GlcNAcylation in kidney cells. Protein O‐GlcNAcylation regulates the function of kidney cells including mesangial cells, podocytes, and proximal tubular cells, and promotes renal interstitial fibrosis, resulting in kidney damage. Current treatments for diabetic nephropathy, such as sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors and renin–angiotensin–aldosterone system (RAAS) inhibitors, delay disease progression, and suppress protein O‐GlcNAcylation.Conclusions: Increased protein O‐GlcNAcylation mediates renal cell damage and promotes renal interstitial fibrosis, leading to diabetic nephropathy. Although the full significance of inhibition of O‐GlcNAcylation is not yet understood, it may represent a novel target for treating diabetic nephropathy.


  • Open Access

    A Novel Role of Hyaluronan and its Membrane Receptors, CD44 and RHAMM in Obesity-Related Glomerulopathy

    by Bingxue Qi, Vishal Musale, Xiong Weng, Ayman K. Banah, Colin E. Murdoch, Abigail C. Lay, Kate J. Heesom, Wenjun Ju, Markus Bitzer, Claire Hills, et al.

    Obesity-related glomerulopathy (ORG) contributes to diabetic nephropathy and kidney cancer, leading to chronic/end-stage kidney disease. To date, treatments for ORG are limited because of incomplete understanding of the disease pathogenesis. Here, we identified a novel role for hyaluronan (HA) and its membrane receptors, CD44 and RHAMM in obesity-associated renal inflammation, fibrosis, tubular injury, and kidney dysfunction. Pharmacological and genetic ablation of HA, CD44 or RHAMM reversed these renal disorders induced by high fat diet feeding in mice in vivo . Increased HA content, and CD44 and RHAMM expression damaged the kidney via activation of TGF-β1/Smad2/3, P38/JNK MAPK and ROCK/ERK pathways. We further established a link between renal insulin resistance and ECM remodelling using human kidney cells in vitro , shedding mechanistic insight into the role of HA, CD44 and RHAMM in the pathogenesis of ORG. Furthermore, in human kidney biopsies gene expression of CD44 and RHAMM was increased in chronic kidney disease and diabetic nephropathy, and their levels were correlated with markers of kidney (dys)function (GFR, serum creatinine, proteinuria). Our findings provide evidence for HA-CD44/RHAMM as a potential therapeutic target in ORG and consequent prevention of chronic kidney disease.


  • Open Access

    Limiting extracellular matrix expansion in diet-induced obese mice reduces cardiac insulin resistance and prevents myocardial remodelling

    by Vishal Musale, Colin E. Murdoch, Ayman K. Banah, Annie Hasib, Chandani K. Hennayake, Bo Dong, Chim C. Lang, David H. Wasserman, Li Kang


  • Open Access

    Deletion of CD44 promotes adipogenesis by regulating PPARγ and cell cycle-related pathways

    by Xiong Weng, Hao Jiang, David J Walker, Houjiang Zhou, De Lin, Jing Wang, Li Kang

    CD44, a cell surface adhesion receptor and stem cell biomarker, is recently implicated in chronic metabolic diseases. Ablation of CD44 ameliorates adipose tissue inflammation and insulin resistance in obesity. Here, we investigated cell type-specific CD44 expression in human and mouse adipose tissue and further studied how CD44 in preadipocytes regulates adipocyte function. Using Crispr Cas9-mdediated gene deletion and lentivirus-mediated gene re-expression, we discovered that deletion of CD44 promotes adipocyte differentiation and adipogenesis, whereas re-expression of CD44 abolishes this effect and decreases insulin responsiveness and adiponectin secretion in 3T3-L1 cells. Mechanistically, CD44 does so via suppressing Pparg expression. Using quantitative proteomics analysis, we further discovered that cell cycle-regulated pathways were mostly decreased by deletion of CD44. Indeed, re-expression of CD44 moderately restored expression of proteins involved in all phases of the cell cycle. These data were further supported by increased preadipocyte proliferation rates in CD44-deficient cells and re-expression of CD44 diminished this effect. Our data suggest that CD44 plays a crucial role in regulating adipogenesis and adipocyte function possibly through regulating PPARγ and cell cycle-related pathways. This study provides evidence for the first time that CD44 expressed in preadipocytes plays key roles in regulating adipocyte function outside immune cells where CD44 is primarily expressed. Therefore, targeting CD44 in (pre)adipocytes may provide therapeutic potential to treat obesity-associated metabolic complications.


  • Open Access

    Extracellular Matrix Abnormalities Contribute to Cardiac Insulin Resistance and Associated Dysfunction in Diet-induced Obese Mice

    by Vishal Musale, Colin E. Murdoch, Ayman K. Banah, Annie Hasib, Chandani K. Hennayake, Bo Dong, Chim C. Lang, David H. Wasserman, Li Kang

    Increased deposition of extracellular matrix (ECM) components such as collagens and hyaluronan contributes to the pathogenesis of obesity-associated insulin resistance in muscle, liver, and adipose tissue. Despite the significance of the heart in cardiovascular and metabolic diseases, maladaptive ECM remodelling in obesity-associated cardiac insulin resistance and cardiac dysfunction has not been studied. Using genetic and pharmacological approaches in mice fed a high fat (HF) diet, we demonstrated a tight association between increased ECM deposition with cardiac insulin resistance. Increased collagen deposition by genetic deletion of matrix metalloproteinase 9 (MMP9) exacerbated cardiac insulin resistance and decreased hyaluronan deposition by treatment with PEGylated human recombinant hyaluronidase PH20 (PEGPH20) improved cardiac insulin resistance in obese mice. These relationships corresponded to functional changes in the heart. PEGPH20 treatment in obese mice ameliorated HF diet-induced abnormal myocardial remodelling. In addition to hyaluronan, increased collagen deposition is a characteristic of the obese mouse heart. We further demonstrated that pirfenidone, a clinically available anti-fibrotic medication which inhibits collagen expression, improved cardiac insulin resistance and cardiac function in obese mice. Our results provide important new insights into the role of ECM remodelling in the pathogenesis of cardiac insulin resistance and associated dysfunction in obesity of distinct mouse models. These findings support the novel therapeutic potential of targeting early cardiac ECM abnormalities in the prevention and treatment of obesity-related cardiovascular complications.


  • Open Access

    Deletion of CD44 promotes adipogenesis by regulating PPARɣ and cell cycle-related pathways

    by Xiong Weng, Hao Jiang, Houjiang Zhou, De Lin, Jing Wang, Li Kang

    CD44, a cell surface adhesion receptor and stem cell biomarker, is recently implicated in chronic metabolic diseases. Ablation of CD44 ameliorates adipose tissue inflammation and insulin resistance in obesity. Here, we investigated cell type specific CD44 expression in human and mouse adipose tissue and further studied how CD44 in preadipocytes regulates adipocyte function. Using Crispr Cas9-mdediated gene deletion and lentivirus-mediated gene re-expression, we discovered that deletion of CD44 promotes adipocyte differentiation and adipogenesis, whereas re-expression of CD44 abolishes this effect and decreases insulin responsiveness and adiponectin secretion in 3T3-L1 cells. Mechanistically, CD44 does so via suppressing Pparg expression. Using quantitative proteomics analysis, we further discovered that cell cycle-regulated pathways were mostly decreased by deletion of CD44. Indeed, re-expression of CD44 moderately restored expression of proteins involved in all phases of the cell cycle. Our data suggest that CD44 plays a crucial role in regulating adipogenesis and adipocyte function possibly through regulating PPAR☐ and cell cycle-related pathways. This study provides evidence for the first time that CD44 expressed in preadipocytes plays key roles in regulating adipocyte function outside immune cells where CD44 is primarily expressed. Therefore, targeting CD44 in (pre)adipocytes may provide therapeutic potential to treat obesity-associated metabolic complications.


  • Open Access

    Extracellular matrix remodelling in obesity and metabolic disorders

    by Vishal Musale, David H Wasserman, Li Kang

    Obesity causes extracellular matrix (ECM) remodelling which can develop into serious pathology and fibrosis, having metabolic effects in insulin-sensitive tissues. The ECM components may be increased in response to overnutrition. This review will focus on specific obesity-associated molecular and pathophysiological mechanisms of ECM remodelling and the impact of specific interactions on tissue metabolism. In obesity, a complex network of signalling molecules such as cytokines and growth factors has been implicated in fibrosis. Increased ECM deposition contributes to the pathogenesis of insulin resistance at least in part through the activation of cell surface integrin receptors and CD44 signalling cascades. These cell surface receptors transmit signals to the cell adhesome which orchestrates an intracellular response that adapts to the extracellular environment. Matrix proteins, glycoproteins, and polysaccharides interact through ligand-specific cell surface receptors that interact with the cytosolic adhesion proteins to elicit specific actions. Cell adhesion proteins may have catalytic activity or serve as scaffolds. The vast number of cell surface receptors and the complexity of the cell adhesome have made study of their roles challenging in health and disease. Further complicating the role of ECM-cell receptor interactions is the variation between cell types. This review will focus on recent insights gained from studies of two highly conserved, ubiquitous axes and how they contribute to insulin resistance and metabolic dysfunction in obesity. These are the collagen-integrin receptor-IPP (ILK-PINCH-Parvin) axis and the hyaluronan-CD44 interaction. We speculate that targeting ECM components or their receptor-mediated cell signalling may provide novel insights into the treatment of obesity-associated cardiometabolic complications.